Physician AI Platform Doximity Reports Explosive Growth as Doctors Embrace Clinical Workflow Tools
The digital health company serving 85% of U.S. physicians saw AI search queries surge over 25% and workflow-active prescribers jump more than 30% as its clinical assistant topped national benchmarks.
Doximity, the professional network serving more than 85% of U.S. physicians, reported accelerating adoption of its AI-powered clinical tools in fiscal Q1 2027, signaling that physician-focused artificial intelligence is moving from experimentation to routine clinical use. The company's AI Search queries increased more than 25% quarter-over-quarter, while workflow active prescribers grew over 30% year-over-year, according to recent financial results.
The growth metrics suggest that integrated AI tools embedded within existing physician workflows are gaining significantly more traction than standalone applications, offering a potential roadmap for healthcare AI adoption across the industry.
Clinical AI Assistant Achieves Top Benchmark Performance
Doximity's clinical AI assistant, Doximity Ask (formerly DoxGPT), achieved top performance among U.S.-based models in the NOHARM benchmark, a measure of AI safety and accuracy in healthcare applications. The platform's suite of HIPAA-compliant AI tools includes PeerCheck, Scribe for ambient clinical documentation, an AI-powered Dialer, prescription drug research capabilities, and Amion scheduling integration.
The company's ability to maintain strong adoption across multiple AI applications suggests physicians are finding value in a comprehensive, integrated approach rather than adopting individual point solutions. With more than 85% of U.S. physicians across specialties already using the Doximity platform, the company holds a significant distribution advantage over competitors entering the clinical AI space.
Financial Performance Reflects AI Investment Costs
Doximity reported fiscal Q1 2027 revenue of $156.6 million, representing a 7% year-over-year increase from $145.9 million in the prior year period. However, adjusted EBITDA margin compressed to 47.7% ($74.8 million) from 54.7% ($79.8 million) in the previous year, indicating ongoing investment in AI development and infrastructure.
The company posted net income of $24.3 million and non-GAAP net income of $55 million, while free cash flow decreased to $39.6 million from $60.1 million in the prior year. For fiscal Q2 2027, Doximity guided revenue to $170-171 million with adjusted EBITDA of $80.5-81.5 million. Full-year fiscal 2027 guidance projects revenue of $671-681 million and adjusted EBITDA of $309-329 million.
The margin compression reflects the reality that developing and deploying clinical-grade AI tools requires substantial ongoing investment, even as adoption accelerates.
Implications for Healthcare AI Adoption
Doximity's results demonstrate that healthcare AI tools can achieve commercial viability and rapid adoption when embedded in platforms physicians already use daily, rather than requiring separate logins or workflow disruptions. The 30% year-over-year growth in workflow active prescribers suggests physicians are moving beyond curiosity-driven experimentation to routine reliance on AI-assisted tools for clinical documentation, drug research, and decision support.
For competitors in the clinical AI space, Doximity's performance creates a high bar: achieving both benchmark-leading accuracy and seamless workflow integration while maintaining HIPAA compliance across a comprehensive tool suite. The company's existing relationship with 85% of U.S. physicians provides a distribution advantage that standalone AI vendors will find difficult to replicate.
Sources
Companies in this article
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.